Ann Folkins

Publications

• Hereditary gynaecological malignancies: advances in screening and treatment. Folkins AK, Longacre TA. Histopathology. 2013; 62 (1): 2-30
• The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mehra KK, Chang MC, Folkins AK, Raho CJ, Lima JF, Yuan L, Mehrad M, Tworoger SS, Crum CP, Saleemuddin A. Mod Pathol. 2011; 24 (1): 152-6
• Utility of chromosomal chromogenic in situ hybridization as an alternative to flow cytometry and cytogenetics in the diagnosis of early partial hydatidiform moles: a validation study. Folkins A, Cruz L, Goldstein DP, Berkowitz RS, Crum C, Kindelberger D. J Reprod Med. 2010 Jul-Aug; 55 (7-8): 275-8
• Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Folkins AK, Nevadunsky NS, Saleemuddin A, Jarboe EA, Muto MG, Feltmate CM, Crum CP, Hirsch MS. Mod Pathol. 2010; 23 (8): 1073-9
• Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Folkins AK, Saleemuddin A, Garrett LA, Garber JE, Muto MG, Tworoger SS, Crum CP. Gynecol Oncol. 2009; 115 (1): 108-11
• Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP. Mod Pathol. 2009; 22 (8): 985-8
• Precursors to pelvic serous carcinoma and their clinical implications. Folkins AK, Jarboe EA, Roh MH, Crum CP. Gynecol Oncol. 2009; 113 (3): 391-6
• Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Histopathology. 2009; 55 (5): 619
• A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP. Gynecol Oncol. 2008; 109 (2): 168-73
• Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR. Int J Gynecol Pathol. 2008; 27 (3): 390-7
• Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, Tworoger S. Gynecol Oncol. 2008; 111 (2): 226-32
• Serous carcinogenesis in the fallopian tube: a descriptive classification. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP. Int J Gynecol Pathol. 2008; 27 (1): 1-9
• Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Histopathology. 2008; 53 (2): 127-38
• Improving the Deaf community's access to prostate and testicular cancer information: a survey study. Folkins A, Sadler GR, Ko C, Branz P, Marsh S, Bovee M. BMC Public Health. 2005: 5 63
• Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Cancer. 2002; 95 (5): 1009-15